Cargando…

Impaired insulin secretion predicting unstable glycemic variability and time below range in type 2 diabetes patients regardless of glycated hemoglobin or diabetes treatment

AIMS/INTRODUCTION: To identify the coefficient of variation (CV) threshold for unstable glucose variability (GV) and hypoglycemia, and to characterize a patient population with unstable GV and hypoglycemia. MATERIALS AND METHODS: This was an observational study that enrolled 284 Japanese outpatients...

Descripción completa

Detalles Bibliográficos
Autores principales: Miya, Aika, Nakamura, Akinobu, Handa, Takahisa, Nomoto, Hiroshi, Kameda, Hiraku, Cho, Kyu Yong, Nagai, So, Miyoshi, Hideaki, Atsumi, Tatsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089015/
https://www.ncbi.nlm.nih.gov/pubmed/33021063
http://dx.doi.org/10.1111/jdi.13426
_version_ 1783686959920578560
author Miya, Aika
Nakamura, Akinobu
Handa, Takahisa
Nomoto, Hiroshi
Kameda, Hiraku
Cho, Kyu Yong
Nagai, So
Miyoshi, Hideaki
Atsumi, Tatsuya
author_facet Miya, Aika
Nakamura, Akinobu
Handa, Takahisa
Nomoto, Hiroshi
Kameda, Hiraku
Cho, Kyu Yong
Nagai, So
Miyoshi, Hideaki
Atsumi, Tatsuya
author_sort Miya, Aika
collection PubMed
description AIMS/INTRODUCTION: To identify the coefficient of variation (CV) threshold for unstable glucose variability (GV) and hypoglycemia, and to characterize a patient population with unstable GV and hypoglycemia. MATERIALS AND METHODS: This was an observational study that enrolled 284 Japanese outpatients with type 2 diabetes who underwent continuous glucose monitoring. The C‐peptide index (CPI = [(fasting serum C‐peptide) / (plasma glucose)] × 100) was used as a marker of endogenous insulin secretion. The CV threshold between stable and unstable GV was defined as the upper limit of the CV distribution in the subgroup of patients who did not receive insulin nor insulin secretagogues (relatively stable GV subgroup, n = 104). The optimal CV range corresponding to time below target range ≥4% was determined for all patients using receiver operating characteristic curve analysis. Various characteristics of patients with unstable GV and hypoglycemia were extracted using multivariate logistic regression analysis. RESULTS: The upper limit of the CV in the relatively stable GV subgroup was 40. The optimal CV range corresponding to time below target range ≥4% was also defined as CV ≥40 (area under the curve 0.85) for all patients. The CPI was an independent risk for CV ≥40 (odds ratio 0.17, 95% confidence interval 0.04–0.50, P < 0.01). The optimal cut‐off point for CPI to predict a CV cut‐off value of 40 was equivalent to 0.81 (area under the curve 0.80). CONCLUSIONS: A CV of 40 discriminates unstable GV and hypoglycemia from stable GV in Japanese outpatients with type 2 diabetes. Impaired insulin secretion might affect the stability of GV.
format Online
Article
Text
id pubmed-8089015
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-80890152021-05-10 Impaired insulin secretion predicting unstable glycemic variability and time below range in type 2 diabetes patients regardless of glycated hemoglobin or diabetes treatment Miya, Aika Nakamura, Akinobu Handa, Takahisa Nomoto, Hiroshi Kameda, Hiraku Cho, Kyu Yong Nagai, So Miyoshi, Hideaki Atsumi, Tatsuya J Diabetes Investig Articles AIMS/INTRODUCTION: To identify the coefficient of variation (CV) threshold for unstable glucose variability (GV) and hypoglycemia, and to characterize a patient population with unstable GV and hypoglycemia. MATERIALS AND METHODS: This was an observational study that enrolled 284 Japanese outpatients with type 2 diabetes who underwent continuous glucose monitoring. The C‐peptide index (CPI = [(fasting serum C‐peptide) / (plasma glucose)] × 100) was used as a marker of endogenous insulin secretion. The CV threshold between stable and unstable GV was defined as the upper limit of the CV distribution in the subgroup of patients who did not receive insulin nor insulin secretagogues (relatively stable GV subgroup, n = 104). The optimal CV range corresponding to time below target range ≥4% was determined for all patients using receiver operating characteristic curve analysis. Various characteristics of patients with unstable GV and hypoglycemia were extracted using multivariate logistic regression analysis. RESULTS: The upper limit of the CV in the relatively stable GV subgroup was 40. The optimal CV range corresponding to time below target range ≥4% was also defined as CV ≥40 (area under the curve 0.85) for all patients. The CPI was an independent risk for CV ≥40 (odds ratio 0.17, 95% confidence interval 0.04–0.50, P < 0.01). The optimal cut‐off point for CPI to predict a CV cut‐off value of 40 was equivalent to 0.81 (area under the curve 0.80). CONCLUSIONS: A CV of 40 discriminates unstable GV and hypoglycemia from stable GV in Japanese outpatients with type 2 diabetes. Impaired insulin secretion might affect the stability of GV. John Wiley and Sons Inc. 2020-11-09 2021-05 /pmc/articles/PMC8089015/ /pubmed/33021063 http://dx.doi.org/10.1111/jdi.13426 Text en © 2020 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Articles
Miya, Aika
Nakamura, Akinobu
Handa, Takahisa
Nomoto, Hiroshi
Kameda, Hiraku
Cho, Kyu Yong
Nagai, So
Miyoshi, Hideaki
Atsumi, Tatsuya
Impaired insulin secretion predicting unstable glycemic variability and time below range in type 2 diabetes patients regardless of glycated hemoglobin or diabetes treatment
title Impaired insulin secretion predicting unstable glycemic variability and time below range in type 2 diabetes patients regardless of glycated hemoglobin or diabetes treatment
title_full Impaired insulin secretion predicting unstable glycemic variability and time below range in type 2 diabetes patients regardless of glycated hemoglobin or diabetes treatment
title_fullStr Impaired insulin secretion predicting unstable glycemic variability and time below range in type 2 diabetes patients regardless of glycated hemoglobin or diabetes treatment
title_full_unstemmed Impaired insulin secretion predicting unstable glycemic variability and time below range in type 2 diabetes patients regardless of glycated hemoglobin or diabetes treatment
title_short Impaired insulin secretion predicting unstable glycemic variability and time below range in type 2 diabetes patients regardless of glycated hemoglobin or diabetes treatment
title_sort impaired insulin secretion predicting unstable glycemic variability and time below range in type 2 diabetes patients regardless of glycated hemoglobin or diabetes treatment
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089015/
https://www.ncbi.nlm.nih.gov/pubmed/33021063
http://dx.doi.org/10.1111/jdi.13426
work_keys_str_mv AT miyaaika impairedinsulinsecretionpredictingunstableglycemicvariabilityandtimebelowrangeintype2diabetespatientsregardlessofglycatedhemoglobinordiabetestreatment
AT nakamuraakinobu impairedinsulinsecretionpredictingunstableglycemicvariabilityandtimebelowrangeintype2diabetespatientsregardlessofglycatedhemoglobinordiabetestreatment
AT handatakahisa impairedinsulinsecretionpredictingunstableglycemicvariabilityandtimebelowrangeintype2diabetespatientsregardlessofglycatedhemoglobinordiabetestreatment
AT nomotohiroshi impairedinsulinsecretionpredictingunstableglycemicvariabilityandtimebelowrangeintype2diabetespatientsregardlessofglycatedhemoglobinordiabetestreatment
AT kamedahiraku impairedinsulinsecretionpredictingunstableglycemicvariabilityandtimebelowrangeintype2diabetespatientsregardlessofglycatedhemoglobinordiabetestreatment
AT chokyuyong impairedinsulinsecretionpredictingunstableglycemicvariabilityandtimebelowrangeintype2diabetespatientsregardlessofglycatedhemoglobinordiabetestreatment
AT nagaiso impairedinsulinsecretionpredictingunstableglycemicvariabilityandtimebelowrangeintype2diabetespatientsregardlessofglycatedhemoglobinordiabetestreatment
AT miyoshihideaki impairedinsulinsecretionpredictingunstableglycemicvariabilityandtimebelowrangeintype2diabetespatientsregardlessofglycatedhemoglobinordiabetestreatment
AT atsumitatsuya impairedinsulinsecretionpredictingunstableglycemicvariabilityandtimebelowrangeintype2diabetespatientsregardlessofglycatedhemoglobinordiabetestreatment